Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
37.02
-0.18 (-0.48%)
At close: May 16, 2025, 4:00 PM
37.74
+0.72 (1.94%)
After-hours: May 16, 2025, 4:34 PM EDT
PRAX Revenue
Praxis Precision Medicines had revenue of $8.12M in the twelve months ending March 31, 2025, up 270.02% year-over-year. In the year 2024, Praxis Precision Medicines had annual revenue of $8.55M with 249.53% growth.
Revenue (ttm)
$8.12M
Revenue Growth
+270.02%
P/S Ratio
89.77
Revenue / Employee
$70,017
Employees
116
Market Cap
754.06M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PRAX News
- 9 days ago - Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside - Benzinga
- 14 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies - GlobeNewsWire
- 6 weeks ago - Praxis Precision Medicines to Participate in Upcoming April Conferences - GlobeNewsWire
- 2 months ago - Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade) - Seeking Alpha
- 2 months ago - Praxis Precision Medicines Provides Update on Essential3 and Corporate Update - GlobeNewsWire
- 3 months ago - Praxis Precision Medicines to Present at Two February Investor Conferences - GlobeNewsWire